<DOC>
	<DOCNO>NCT00839449</DOCNO>
	<brief_summary>Cerebral vasospasm follow subarachnoid hemorrhage ( SAH ) common cause morbidity mortality . Recent study indicate Rho-kinase play important role occurrence cerebral vasospasm . Eicosapentaenoic acid ( EPA ) inhibit sphingosylphosphorylcholine ( SPC ) -induced Rho-kinase activation vitro . So study examines whether EPA prevent cerebral vasospasm occurrence SAH patient .</brief_summary>
	<brief_title>Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study</brief_title>
	<detailed_description>Cerebral vasospasm occasionally see subarachnoid hemorrhage ( SAH ) due rupture intracranial aneurysm common cause morbidity mortality case . Recent study indicate Rho-kinase play important role cerebral vasospasm numerous agent , thromboxane A2 ( TXA2 ) , sphingosylphosphorylcholine ( SPC ) arachidonic acid ( AA ) , activate Rho-kinase directly receptors cell membrane ; among agent , SPC describe novel messenger Rho-kinase-mediated Ca2+ sensitization vascular smooth muscle contraction . Eicosapentaenoic acid ( EPA ) recently report inhibit SPC-induced Rho-kinase activation vitro , thereby vascular smooth muscle contraction , inhibition Src family protein tyrosine kinases translocation . Moreover , concentration AA increase cerebrospinal fluid patient SAH , suggest substance potential role occurrence cerebral vasospasm follow SAH , EPA know change constitution ratio AA EPA cell membrane phospholipid , result inhibition TXA2 synthesis . These observation lead u hypothesize EPA may inhibit cerebral vasospasm follow SAH inhibition Rho-kinase activation .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Vasospasm , Intracranial</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Subarachnoid hemorrhage ( SAH ) The ruptured cerebral aneurysm conform cerebral angiography The patient treat craniotomy clip application within 72h onset SAH Traumatic mycotic aneurysm A history complication serious stroke Moya Moya disease A history SAH Complication serious heart hepatic disease infection renal failure Malignant tumor Patients judge inappropriate physician charge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>subarachnoid hemorrhage</keyword>
	<keyword>cerebral vasospasm</keyword>
	<keyword>eicosapentaenoic acid</keyword>
</DOC>